中广核技: 第十届监事会第十四次会议决议公告

Group 1 - The core point of the announcement is the approval of a capital increase by the controlling shareholder, China General Nuclear Power Corporation, to its wholly-owned subsidiary, China General Nuclear Medical Technology (Mianyang) Co., Ltd., amounting to 500 million yuan, which is seen as beneficial for the company's nuclear medical business development [1][2] - The supervisory board held a meeting on June 5, 2025, where the decision regarding the capital increase was made, with all members present either in person or via remote voting [1] - The resolution regarding the capital increase was passed with a unanimous vote of 3 in favor, with no votes against or abstentions, and it will be submitted for approval at the 2024 annual shareholders' meeting [1] Group 2 - The supervisory board also approved amendments to the company's articles of association, which will also be submitted for approval at the 2024 annual shareholders' meeting [2] - The announcement emphasizes that the related party transaction was conducted fairly and reasonably, ensuring no harm to the company or its shareholders, particularly minority and non-related shareholders [1]